Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andrew Dervan"'
Autor:
Amrit P. Singh, Frank Schmitz, Adam Z. Rosenthal, Madhav V. Dhodapkar, Antje Hoering, Daisy Alapat, Yan Ren, Maurizio Zangari, Kelsie Smith, Samuel A. Danziger, Jake Gockley, Andrew Dervan, Alexander V. Ratushny, Mark McConnell, Robert M. Hershberg, Suzana Couto, Brian A Walker, Faith E. Davies, Alison Fitch, Wilbert B. Copeland, Gareth J. Morgan, Bart Barlogie, Phil Farmer, David J. Reiss, Brian Fox, Mary H. Young, Frits van Rhee, Cody Ashby, Katie Newhall, Nathan Petty, Michael A Bauer, Robert Z. Orlowski, Matthew Trotter
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 17, Iss 11, p e1003323 (2020)
PLoS Medicine, Vol 17, Iss 11, p e1003323 (2020)
Background The tumor microenvironment (TME) is increasingly appreciated as an important determinant of cancer outcome, including in multiple myeloma (MM). However, most myeloma microenvironment studies have been based on bone marrow (BM) aspirates, w
Autor:
Alexander V. Ratushny, Rob Hershberg, Mary Young, Faith E. Davies, Antje Hoering, Frits van Rhee, Adam Rosenthal, Gareth J. Morgan, Matthew Trotter, Bart Barlogie, Brian A Walker, Maurizio Zangari, Mark McConnell, Brian Fox, Katie Newhall, Jake Gockley, Andrew Dervan, Nathan Petty, Michael A Bauer, Wilbert B. Copeland, Samuel A. Danziger, Cody Ashby, Alison Fitch, David J. Reiss, Frank Schmitz, Phil Farmer
Publikováno v:
Blood. 132:1882-1882
Introduction The multiple myeloma (MM) tumor microenvironment (TME) strongly influences patient outcomes as evidenced by the success of immunomodulatory therapies. To develop precision immunotherapeutic approaches, it is essential to identify and enu
Autor:
John G. Gribben, Andrew Dervan, Teri Foy, Alison Fitch, Katie Newhall, Elizabeth Whalen, Mary H. Young, Mark Tometsko, Jamie Cavenagh, Ethan G. Thompson, Brian Fox, Samuel A. Danziger, Frances Seymour
Publikováno v:
Blood. 132:3296-3296
Introduction Relapsed and refractory multiple myeloma (RRMM) remains a challenging disease to treat due to its heterogeneity and complexity. There is an urgent need for novel combination strategies, including immunotherapy. The study of the tumour an
Autor:
Michael A Bauer, Cody Ashby, Ruslana Tytarenko, Purvi Patel, Sharmilan Thanendrarajan, Faith E. Davies, Jonathan J Keats, Frits van Rhee, Anjan Thakurta, Erin Flynt, Maurizio Zangari, Daniel Auclair, Aneta Mikulasova, Brian A Walker, Christopher P. Wardell, Jake Gockley, Andrew Dervan, Maria Ortiz, Yan Wang, Carolina Schinke, Gareth J. Morgan
Publikováno v:
Blood. 132:408-408
Introduction: Chromothripsis and chromoplexy are gross structural events that deregulate multiple genes simultaneously and may help explain rapid changes in clinical behavior. Previous screening studies in multiple myeloma (MM) using copy number arra
Autor:
Jake Gockley, Andrew Dervan, Teri Foy, Brian A Walker, Mark McConnell, Alison Fitch, David J. Reiss, Gareth J. Morgan, Frank Schmitz, Samuel A. Danziger, Sarah K. Johnson, Katie Newhall, Alexander V. Ratushny, Robert M. Hershberg, Wilbert B. Copeland, Mary H. Young
Publikováno v:
Blood. 132:243-243
Introduction The multistep progression of multiple myeloma from a normal plasma cell to a system with the features of invasive cancer provides a unique opportunity to understand the co-evolution of the malignant clone within its microenvironment. Und
Autor:
Hongyue Dai, Thomas Yu, Gareth J. Morgan, Doug Bassett, Brian A Walker, Nikhil C. Munshi, Michael Mason, Dirk Hose, Matthew Trotter, Frank Schmitz, Fadi Towfic, Hartmut Goldschmidt, Justin Guinney, Ken Shain, Anjan Thakurta, Erin Flynt, Michael Amatangelo, Andrew Dervan, Alex Ratushny, Konstantinos Mavrommatis, Dan Rozelle, Brian S. White, Mehmet Kemal Samur, Daniel Auclair
Publikováno v:
Cancer Research. 77:4725-4725
Introduction: Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becomin